The DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.
Type I interferon responses in rhesus macaques prevent SIV infection and slow disease progression
Open accessAbstract
Inflammation in HIV infection is predictive of non-AIDS morbidity and death, higher set point plasma virus load and virus acquisition; thus, therapeutic agents are in development to reduce its causes and consequences. However, inflammation may simultaneously confer both detrimental and beneficial effects. This dichotomy is particularly applicable to type I interferons (IFN-I) which, while contributing to innate control of infection, also provide target cells for the virus during acute infection, impair CD4 T-cell recovery, and are associated with disease progression. Here we manipulated IFN-I signalling in rhesus macaques (Macaca mulatta) during simian immunodeficiency virus (SIV) transmission and acute infection with two complementary in vivo interventions. We show that blockade of the IFN-I receptor caused reduced antiviral gene expression, increased SIV reservoir size and accelerated CD4 T-cell depletion with progression to AIDS despite decreased T-cell activation. In contrast, IFN-α2a administration initially upregulated expression of antiviral genes and prevented systemic infection. However, continued IFN-α2a treatment induced IFN-I desensitization and decreased antiviral gene expression, enabling infection with increased SIV reservoir size and accelerated CD4 T-cell loss. Thus, the timing of IFN-induced innate responses in acute SIV infection profoundly affects overall disease course and outweighs the detrimental consequences of increased immune activation. Yet, the clinical consequences of manipulation of IFN signalling are difficult to predict in vivo and therapeutic interventions in human studies should be approached with caution.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
STAR: ultrafast universal RNA-seq aligner
Dobin, A., Davis, C. A., Schlesinger, F., Drenkow, J., Zaleski, C., Jha, S., Batut, P., Chaisson, M., & Gingeras, T. R. (2013) · Bioinformatics · doi:10.1093/bioinformatics/bts635 · Cited by 51,709
Differential analysis of gene regulation at transcript resolution with RNA-seq
Trapnell, C., Hendrickson, D. G., Sauvageau, M., Goff, L., Rinn, J. L., & Pachter, L. (2013) · Nature Biotechnology · doi:10.1038/nbt.2450 · Cited by 3,492
A diverse range of gene products are effectors of the type I interferon antiviral response
Schoggins, J. W., Wilson, S. J., Panis, M., Murphy, M. Y., Jones, C. T., Bieniasz, P., & Rice, C. M. (2011) · Nature · doi:10.1038/nature09907 · Cited by 2,433
IRF-7 is the master regulator of type-I interferon-dependent immune responses
Honda, K., Yanai, H., Negishi, H., Asagiri, M., Sato, M., Mizutani, T., Shimada, N., Ohba, Y., Takaoka, A., Yoshida, N., et al. (2005) · Nature · doi:10.1038/nature03464 · Cited by 2,245
Immunomodulatory functions of type I interferons
González-Navajas, J. M., Lee, J., David, M., & Raz, E. (2012) · Nature Reviews Immunology · doi:10.1038/nri3133 · Cited by 1,011
Mechanism of action of interferon and ribavirin in treatment of hepatitis C
Feld, J. J., & Hoofnagle, J. H. (2005) · Nature · doi:10.1038/nature04082 · Cited by 992
Pan-viral specificity of IFN-induced genes reveals new roles for cGAS in innate immunity
Schoggins, J. W., MacDuff, D. A., Imanaka, N., Gainey, M. D., Shrestha, B., Eitson, J. L., Mar, K. B., Richardson, R. B., Ratushny, A. V., Litvak, V., et al. (2014) · Nature · doi:10.1038/nature12862 · Cited by 896
Persistent LCMV infection is controlled by blockade of type I interferon signaling
Teijaro, J. R., Ng, C., Lee, A. M., Sullivan, B. M., Sheehan, K. C. F., Welch, M., Schreiber, R. D., Carlos de la Torre, J., & Oldstone, M. B. A. (2013) · Science · doi:10.1126/science.1235214 · Cited by 755
Stacey, A. R., Norris, P. J., Qin, L., Haygreen, E. A., Taylor, E., Heitman, J., Lebedeva, M., DeCamp, A., Li, D., Grove, D., et al. (2009) · Journal of Virology · doi:10.1128/jvi.01844-08 · Cited by 747
Blockade of chronic type I interferon signaling to control persistent LCMV infection
Wilson, E. B., Yamada, D. H., Elsaesser, H., Herskovitz, J., Deng, J., Cheng, G., Aronow, B. J., Karp, C. L., & Brooks, D. G. (2013) · Science · doi:10.1126/science.1235208 · Cited by 709
Glycerol monolaurate prevents mucosal SIV transmission
Li, Q., Estes, J. D., Schlievert, P. M., Duan, L., Brosnahan, A. J., Southern, P. J., Reilly, C. S., Peterson, M. L., Schultz-Darken, N., Brunner, K. G., et al. (2009) · Nature · doi:10.1038/nature07831 · Cited by 638
Self-citationHuman MX2 is an interferon-induced post-entry inhibitor of HIV-1 infection
Goujon, C., Moncorgé, O., Bauby, H., Doyle, T., Ward, C. C., Schaller, T., Hué, S., Barclay, W. S., Schulz, R., & Malim, M. H. (2013) · Nature · doi:10.1038/nature12542 · Cited by 583
Hunt, P. W., Sinclair, E., Rodriguez, B., Shive, C., Clagett, B., Funderburg, N., Robinson, J., Huang, Y., Epling, L., Martin, J. N., et al. (2014) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiu238 · Cited by 478
Vaccine protection against acquisition of neutralization-resistant SIV challenges in rhesus monkeys
Barouch, D. H., Liu, J., Li, H., Maxfield, L. F., Abbink, P., Lynch, D. M., Iampietro, M. J., SanMiguel, A., Seaman, M. S., Ferrari, G., et al. (2012) · Nature · doi:10.1038/nature10766 · Cited by 465
Phenotypic properties of transmitted founder HIV-1
Parrish, N. F., Gao, F., Li, H., Giorgi, E. E., Barbian, H. J., Parrish, E. H., Zajic, L., Iyer, S. S., Decker, J. M., Kumar, A., et al. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1304288110 · Cited by 422
ANTI-RETROVIRAL EFFECTS OF INTERFERON-α IN AIDS-ASSOCIATED KAPOSI'S SARCOMA
Clifford Lane, H., Feinberg, J., Davey, V., Deyton, L., Baseler, M., Manischewitz, J., Masur, H., Kovacs, J., Herpin, B., Walker, R., et al. (1988) · The Lancet · doi:10.1016/s0140-6736(88)90811-2 · Cited by 261
Relative resistance of HIV-1 founder viruses to control by interferon-alpha
Fenton-May, A. E., Dibben, O., Emmerich, T., Ding, H., Pfafferott, K., Aasa-Chapman, M. M., Pellegrino, P., Williams, I., Cohen, M. S., Gao, F., et al. (2013) · Retrovirology · doi:10.1186/1742-4690-10-146 · Cited by 197
Azzoni, L., Foulkes, A. S., Papasavvas, E., Mexas, A. M., Lynn, K. M., Mounzer, K., Tebas, P., Jacobson, J. M., Frank, I., Busch, M. P., et al. (2013) · The Journal of Infectious Diseases · doi:10.1093/infdis/jis663 · Cited by 189
A FOXO3–IRF7 gene regulatory circuit limits inflammatory sequelae of antiviral responses
Litvak, V., Ratushny, A. V., Lampano, A., Schmitz, F., Huang, A. C., Raman, A. T., Rust, A. G., Bergthaler, A., Aitchison, J. D., & Aderem, A. A. (2012) · Nature · doi:10.1038/nature11428 · Cited by 150
Naranbhai, V., Karim, S. S. A., Altfeld, M. A., Samsunder, N., Durgiah, R., Sibeko, S., Karim, Q. A., Carr, W. H., & the CAPRISA004 TRAPS team (2012) · The Journal of Infectious Diseases · doi:10.1093/infdis/jis465 · Cited by 140
Brenchley, J. M., Vinton, C. L., Tabb, B., Hao, X., Connick, E., Paiardini, M., Lifson, J. D., Silvestri, G., & Estes, J. D. (2012) · Blood · doi:10.1182/blood-2012-06-437608 · Cited by 130
Self-citationFernández, S., Tanaskovic, S., Helbig, K. J., Rajasuriar, R., Kramski, M., Murray, J. M., Beard, M. R., Purcell, D., Lewin, S. R., Price, P., et al. (2011) · The Journal of Infectious Diseases · doi:10.1093/infdis/jir659 · Cited by 123
Multifaceted Activities of Type I Interferon Are Revealed by a Receptor Antagonist
Levin, D., Schneider, W. M., Hoffmann, H.-H., Yarden, G., Busetto, A. G., Manor, O., Sharma, N., Rice, C. M., & Schreiber, G. (2014) · Science Signaling · doi:10.1126/scisignal.2004998 · Cited by 113
Self-citationFraietta, J. A., Mueller, Y. M., Yang, G., Boesteanu, A. C., Gracias, D. T., Do, D. H., Hope, J. L., Kathuria, N., McGettigan, S. E., Lewis, M. G., et al. (2013) · PLoS Pathogens · doi:10.1371/journal.ppat.1003658 · Cited by 97
Roberts, L., Passmore, J.-A. S., Mlisana, K. P., Williamson, C. E., Little, F., Bebell, L. M., Walzl, G., Abrahams, M.-R., Woodman, Z., Karim, Q. A., et al. (2011) · The Journal of Infectious Diseases · doi:10.1093/infdis/jir715 · Cited by 86
McElrath, M. J., Smythe, K. S., Randolph‐Habecker, J., Melton, K. R., Goodpaster, T. A., Hughes, S. M., Mack, M., Sato, A., Diaz, G., Steinbach, G., et al. (2013) · JAIDS Journal of Acquired Immune Deficiency Syndromes · doi:10.1097/qai.0b013e3182898392 · Cited by 74
Therapeutic Depletion of Natural Killer Cells Controls Persistent Infection
Waggoner, S. N., Daniels, K. A., & Welsh, R. M. (2013) · Journal of Virology · doi:10.1128/jvi.03002-13 · Cited by 73
Vanderford, T. H., Slichter, C. K., Rogers, K. A., Lawson, B., Obaede, R., Else, J. G., Villinger, F. J., Bosinger, S. E., & Silvestri, G. (2012) · Blood · doi:10.1182/blood-2012-02-411496 · Cited by 54
Self-citationInterferon-Alpha Administration Enhances CD8+ T Cell Activation in HIV Infection
Manion, M. M., Rodriguez, B. A., Medvik, K., Hardy, G. A. D., Harding, C. V., Schooley, R. T., Pollard, R. B., Asmuth, D. M., Murphy, R. L., Barker, E., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0030306 · Cited by 53
A Randomized Trial of Interferon alpha Therapy for HIV Type 1 Infection
Haas, D. W., Lavelle, J. P., Nadler, J. P., Greenberg, S. B., Frame, P. T., Mustafa, N., Clair, M. S., McKinnis, R. A., Dix, L. P., Elkins, M., et al. (2000) · AIDS Research and Human Retroviruses · doi:10.1089/088922200309278 · Cited by 53
Cited by
Molecular and cellular insights into T cell exhaustion
Wherry, E. J., & Kurachi, M. (2015) · Nature Reviews Immunology · doi:10.1038/nri3862 · Cited by 4,652
Type I interferons in infectious disease
McNab, F., Mayer-Barber, K., Sher, A., Wack, A., & O'Garra, A. (2015) · Nature Reviews Immunology · doi:10.1038/nri3787 · Cited by 2,780
CD8 T Cell Exhaustion During Chronic Viral Infection and Cancer
McLane, L. M., Abdel-Hakeem, M. S., & Wherry, E. J. (2019) · Annual Review of Immunology · doi:10.1146/annurev-immunol-041015-055318 · Cited by 1,975
Rothhammer, V., Mascanfroni, I. D., Bunse, L., Takenaka, M. C., Kenison, J. E., Mayo, L., Chao, C.-C., Patel, B., Yan, R., Blain, M., et al. (2016) · Nature Medicine · doi:10.1038/nm.4106 · Cited by 1,559
Channappanavar, R., Fehr, A. R., Vijay, R., Mack, M., Zhao, J., Meyerholz, D. K., & Perlman, S. (2016) · Cell Host & Microbe · doi:10.1016/j.chom.2016.01.007 · Cited by 1,419
Metadata
- Authors
- Sandler, N. G., Bosinger, S. E., Estes, J. D., Zhu, R. T. R., Tharp, G. K., Boritz, E., Levin, D., Wijeyesinghe, S., Makamdop, K. N., del Prete, G. Q., Hill, B. J., Timmer, J. K., Reiss, E., Yarden, G., Darko, S., Contijoch, E., Todd, J. P., Silvestri, G., Nason, M., Norgren Jr, R. B., Keele, B. F., Rao, S., Langer, J. A., Lifson, J. D., Schreiber, G., & Douek, D. C.
- Venue
- Nature
- Published
- 2014-07
- Volume
- 511
- Issue
- 7511
- Pages
- 601-605
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- OpenAlex
- W2032523448
- Cited by
- 461
- References
- 30
- FWCI
- 25.42
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.